| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA01167 |
| P698 | PubMed publication ID | 11756577 |
| P2093 | author name string | Li M | |
| Fujii M | |||
| Dalakas MC | |||
| McElroy B | |||
| Kyhos J | |||
| Lutfi B | |||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stiff-person syndrome | Q1235785 |
| P304 | page(s) | 1870-1876 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | High-dose intravenous immune globulin for stiff-person syndrome | |
| P478 | volume | 345 |
| Q83232977 | 9 Human Immunoglobulins |
| Q29994727 | A case of stiff dog syndrome associated with anti-glutamic acid decarboxylase antibodies |
| Q48021708 | A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome |
| Q44045156 | A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies |
| Q38953401 | A low back pain revealing a stiff-man syndrome |
| Q48154570 | Acute Respiratory Failure in a Patient with Stiff-Person Syndrome |
| Q92266493 | Adolescent Stiff Person Syndrome: Long-Term Symptom Remission on Immunomodulatory Therapy |
| Q34589713 | Advances in the pathogenesis and treatment of patients with stiff person syndrome |
| Q54959224 | Anti-GAD antibody syndrome with concomitant cerebellar ataxia, stiff person syndrome, and limbic encephalitis. |
| Q35182392 | Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. |
| Q33966060 | Antibody-associated diseases of the gray matter of the CNS: diagnosis and treatment |
| Q28264405 | Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes |
| Q35458567 | Brain-reactive antibodies and disease. |
| Q60711956 | Case Study: Anti-GAD Encephalitis |
| Q35947819 | Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition |
| Q36826497 | Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy |
| Q30518011 | Childhood stiff-person syndrome improved with rituximab. |
| Q38050751 | Clinical applications of immunoglobulin: update |
| Q36264883 | Clinical uses of intravenous immunoglobulin. |
| Q34107713 | Cognitive decline in a patient with anti-glutamic acid decarboxylase autoimmunity; case report |
| Q34802779 | Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control study |
| Q53637231 | Current therapies for neuromuscular manifestations of paraneoplastic syndromes. |
| Q57254181 | Current therapies for paraneoplastic neurologic syndromes |
| Q36700047 | Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues |
| Q36484438 | Efficacy of Intravenous Immunoglobulin in Neurological Diseases. |
| Q41107258 | Evaluation of Treatment Outcomes in Patients with Stiff Person Syndrome with Rituximab vs. Standard of Care |
| Q33385332 | Evidence for the use of intravenous immunoglobulins--a review of the literature |
| Q50194673 | From stiff man syndrome to stiff person spectrum disorders |
| Q95840283 | GAD antibodies in neurological disorders - insights and challenges |
| Q33937492 | Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes |
| Q30451984 | Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype |
| Q37237416 | IVIg in other autoimmune neurological disorders: current status and future prospects |
| Q35729575 | Immune mediated diseases and immune modulation in the neurocritical care unit |
| Q92343326 | Improving Ambulation and Minimizing Disability with Therapeutic Plasma Exchange in a Stiff-person Syndrome Patient with Recurrent Falls |
| Q58861264 | Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques |
| Q85018724 | Intravenous IgG for treatment of neuromuscular diseases |
| Q35542385 | Intravenous immune globulins: an update for clinicians |
| Q86705300 | Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies |
| Q33366800 | Intravenous immunoglobulin in neurological disorders: a mechanistic perspective |
| Q38308436 | Intravenous immunoglobulin in neurology--mode of action and clinical efficacy |
| Q82162297 | Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes |
| Q36602775 | Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes |
| Q37873722 | Intravenous immunoglobulin therapy in rheumatic diseases |
| Q36757383 | Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. |
| Q59413122 | La place des immunoglobulines intraveineuses en neurologie |
| Q21136358 | Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome |
| Q37440005 | Losing your nerves? Maybe it's the antibodies |
| Q59812985 | Management of Autoimmune Encephalitis: An Observational Monocentric Study of 38 Patients |
| Q38203801 | Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations |
| Q36993609 | Movement disorders in paraneoplastic and autoimmune disease. |
| Q47623969 | Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology |
| Q82029932 | Muscle cramp syndromes |
| Q35105053 | Neuromuscular complications of cancer |
| Q34359264 | Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome. |
| Q41173378 | New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins |
| Q35172434 | Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy |
| Q58568103 | Pragmatic Treatment of Stiff Person Spectrum Disorders |
| Q27323224 | Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab |
| Q60921333 | Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder |
| Q26864907 | Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies |
| Q36602794 | Rare indications of IVIG therapy in neurological diseases based on case reports and small studies |
| Q26768678 | Recent Advances and Review on Treatment of Stiff Person Syndrome in Adults and Pediatric Patients |
| Q42671923 | Recommendations for the use of albumin and immunoglobulins |
| Q51829793 | Rhabdomyolysis and paraneoplastic stiff-man syndrome with amphiphysin autoimmunity. |
| Q36602771 | Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects |
| Q37703410 | Stiff limb syndrome: a case report |
| Q34607642 | Stiff man syndrome: a diagnostic dilemma in a young female with diabetes mellitus and thyroiditis |
| Q84290573 | Stiff person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab |
| Q36167047 | Stiff person syndrome in South Asia |
| Q48751128 | Stiff person syndrome: advances in pathogenesis and therapeutic interventions |
| Q89469271 | Stiff-person Syndrome with Waldenström Macroglobulinemia |
| Q64993700 | Stiff-person Syndrome. |
| Q56883348 | Stiff-person syndrome |
| Q37179065 | Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease |
| Q37834590 | Stiff-person syndrome: a case report and review of the literature |
| Q83730671 | Surviving stiff-person syndrome: a case report |
| Q26752540 | The Production Processes and Biological Effects of Intravenous Immunoglobulin |
| Q57157350 | The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders |
| Q28295552 | The immunological basis for treatment of stiff person syndrome |
| Q81858038 | The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies |
| Q92573015 | The use of IVIg in fetal and neonatal alloimmune thrombocytopenia- Principles and mechanisms |
| Q47581297 | Therapy with Intravenous Immunoglobulins: Complications and Side-Effects |
| Q42907014 | Treatment of paraneoplastic neurologic disorders |
| Q28206077 | Voltage‐gated potassium channel antibodies in limbic encephalitis |
| Q81741355 | [Current use of immunoglobulins in neurology] |
| Q80953233 | [Immunomodulatory effects of intravenous immunoglobulins] |
| Q81317771 | [Intravenous immunoglobulins: therapeutic indications] |
| Q86560972 | [Stiff man syndrome and variants] |
| Q73507540 | [Therapeutic indications of intravenous immunoglobulins] |
| Q80257893 | [Use of i.v. immunoglobulins in neurology. Evidence-based consensus] |
Search more.